- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01769170
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1200
- Cliniques Universitaires Saint Luc
-
-
Liege
-
Brüssel, Liege, Belgium, 4000
- Centre Hospitalier Universitaire Sart Tilman Liège
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G2C4
- University of Toronto
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Centre Hospitalier Universitaire de Montreal, Hopital Maisonneuve-Rosemont
-
-
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego-Moores Cancer Center
-
Los Angeles, California, United States, 90095
- UCLA Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Northside Hospital
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute-Emory
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 45229
- The Universit of Iowa
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Womens Hospital
-
Boston, Massachusetts, United States, 02115
- Beth Isreal Decaconess Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Detroit, Michigan, United States, 48201
- Harper University Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10029
- Mt. Sinai Medical Center
-
New York, New York, United States, 10065
- Weill Cornell Medical College/NY Presbyterial Hospital
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute/Carolinas Health
-
Durham, North Carolina, United States, 27710
- Duke Cancer Institute
-
Winston-Salem, North Carolina, United States, 27517
- Wake Forest
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
Cincinnati, Ohio, United States, 45236
- The Jewish Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, United States, 15224
- Western Pennsylvania Hospital
-
Pittsburgh, Pennsylvania, United States, 15224
- Allegheny-Singer Research Institute
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Hollings Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center at Dallas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Methodist Healthcare of San Antonio
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah, Huntsman Cancer Institute
-
Salt Lake City, Utah, United States, 84143
- Intermountain Healthcare
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Subjects were required to meet all of the following criteria, as applicable, to be eligible to participate in this study:
- Were allogeneic hematopoietic stem cell transplant (HCT) recipients who had prior evidence of cytomegalovirus (CMV) exposure (CMV-seropositive) before transplantation and were CMV viremia negative at screening and at any other assessments performed prior to the first dose of study drug.
- Were aged ≥18 years.
- If male, were willing to use an acceptable contraceptive method(s) throughout the duration of his participation in the study, i.e., through Week 24, when engaging in sexual intercourse with a female subject of childbearing potential.
- If female of childbearing potential, i.e., not postmenopausal or surgically sterile, were willing to use 2 acceptable contraceptive methods, 1 of which must have been a barrier method, throughout the duration of her participation in the study, i.e., through Week 24, when engaging in sexual intercourse with a nonsterile male partner.
- Were able to begin study drug dosing within 28 days following the qualifying HCT.
- Were able to comfortably ingest and absorb oral medication (in the judgment of the investigator and base don lack of significant gastrointestinal events/medical history).
- Were willing and able to understand and provide written informed consent.
- Were willing and able to participate in all required study activities for the entire duration of the study (i.e., through Week 24).
Exclusion Criteria
Subjects who met any of the following criteria, as applicable, were not eligible to participate in this study:
- Was pregnant or planned to become pregnant during the anticipated duration of her participation in the study (i.e., through Week 24), or was nursing a child.
- Had a positive CMV viremia test (at the designated central virology laboratory or a local virology laboratory) at any time between transplant and the first dose of study drug.
- Weighed ≥120 kg (~265 lbs).
- Had hypersensitivity (not renal dysfunction or eye disorder) to cidofovir (CDV), brincidofovir (BCV), or its excipients.
Had received (or were anticipated to need treatment with) any of the following:
- Ganciclovir, valganciclovir, foscarnet, intravenous CDV, or any other anti-CMV therapy (including CMV immune globulin, cell-based therapies, and investigational anti-CMV drugs, e.g., leflunomide, letermovir, or maribavir) at any time post-transplant;
- Any anti-CMV vaccine at any time;
- Any other investigation drug within 14 days prior to the first dose of study drug (unless prior approval had been received from the Chimerix medical monitor or designee); or
- Prior treatment with BCV at any time.
Were receiving of the following drugs on the first dose of study drug or were anticipated to receive any of these drugs at the doses described after the first dose of study drug:
- Acyclovir orally at >2000 mg total daily dose (TDD) or intravenously at >15 mg/kg TDD;
- Valaciclovir at >3000 mg TDD; or
- Leflunomide at any dose.
- Were receiving digoxin or ketoconazole (other than topical formulations) at the first dose of study drug or were anticipated to need treatment with either digoxin or ketoconazole during the treatment phase (through Week 14).
- Had possible, probably, or definitive CMV disease diagnosed within 6 months prior to first dose of study drug.
- Were infected with HIV (based on serology), or had an active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, as evidence by detectable plasma HCV RNA or HBV DNA, respectively.
- Had received another allogeneic HCT (i.e., other than the qualifying HCT) within 2 years prior to the first dose of study drug.
- Had renal insufficiency, as evidence by an estimated glomerular filtration rate (eGFR) <15 mL/min or required renal dialysis.
- Had hepatic abnormalities as evidence by a screening of alanine aminotransferase or aspartate aminotransferase >5 x the upper limit of normal (ULN), as reported by the central safety laboratory.
- Had a screening total bilirubin >2 x the ULN and direct bilirubin >1.5 x the ULN, as reported by the central safety laboratory.
- Had active solid tumor malignancies with the exception of basal cell carcinoma or the underlying condition necessitating HCT (e.g., lymphomas).
- Had Stage 2 or higher graft versus host disease of the gut or any other GI disease that would have, in the judgment of the investigator, precluded the subject from taking or absorbing oral medication (e.g., clinically active Crohn's disease, ischemic colitis, moderate or severe ulcerative colitis, small bowel resection, ileus, or any condition expected to require abdominal surgery during the course of study participation).
- Had any other condition, including abnormal laboratory values, that would have, in the judgement of the investigator, put the subject at increased risk by participating in the study or would have interfered with the conduct or planned analyses of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Matching placebo administered orally twice weekly
|
|
ACTIVE_COMPARATOR: Brincidofovir
100 mg brincidofovir administered orally twice weekly
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant
Time Frame: 24 weeks
|
Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes:
CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test. |
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Clinically Significant CMV Infection Through Week 14
Time Frame: 14 weeks
|
The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14. Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV. |
14 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMX001-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV
-
St George's, University of LondonSt George's University Hospitals NHS Foundation TrustActive, not recruitingCMV | Congenital Cmv | Maternal Infections Affecting Fetus or Newborn | Shedding VirusUnited Kingdom
-
Grupo Espanol de trasplantes hematopoyeticos y...Not yet recruiting
-
QIAGEN Gaithersburg, IncTerminated
-
Medical University of South CarolinaTakedaRecruitingCMV | Transplant ComplicationUnited States
-
Meridian Bioscience, Inc.Completed
-
University Hospital, LimogesUniversity Hospital, LilleCompleted
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplantation | CMV Reactivation | Autologous CMV Specific CD8+ T CellsUnited Kingdom
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Fundación para la Investigación del Hospital Clínico...Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States